Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6321535rdf:typepubmed:Citationlld:pubmed
pubmed-article:6321535lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C1123019lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C0010132lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C0030685lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C0680255lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C0391871lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C1283071lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C1963578lld:lifeskim
pubmed-article:6321535lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:6321535pubmed:issue4lld:pubmed
pubmed-article:6321535pubmed:dateCreated1984-4-20lld:pubmed
pubmed-article:6321535pubmed:abstractTextThe response of plasma proopiolipomelanocortin-derived peptide levels to synthetic ovine corticotropin-releasing hormone (CRH) was studied in six normal men. CRH was given as a 30-sec iv injection of 30 micrograms/kg body weight in the late afternoon, and blood samples were drawn for up to 16 h thereafter. Low levels of immunoreactive (IR)-ACTH, IR-beta-endorphin and IR-lipotropins (LPH) were measured before CRH administration. All subjects had prompt, concomitant, biphasic, and prolonged release of all of these proopiolipomelanocortin-derived peptides. The plasma levels of these IR-peptides rose in all subjects by 5 min after CRH, reached a first peak at 10-15 min, fell until 90 min, rose to a second peak at 2-4 h, and then gradually declined over several hours. The molar concentrations of the IR-peptides closely paralleled one another at all times, especially during the first 90 min after CRH administration. Later, IR-LPH increased slightly more and remained slightly higher than did the other IR-peptides, although the difference was not significant. This observation probably reflects the longer plasma disappearance half-life of IR-LPH. The maximum change (mean +/- SEM) in the concentration of these IR-peptides was similar: IR-ACTH, 18.0 +/- 4.0; IR-LPH, 20.5 +/- 4.0; and IR-beta-endorphin, 16.9 +/- 3.2 fmol/ml. The next morning's circadian rise in IR-peptides was blocked, presumably due to negative feedback inhibition of the hypothalamic-pituitary-adrenal axis by the prolonged high plasma cortisol levels stimulated by CRH the previous evening.lld:pubmed
pubmed-article:6321535pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:languageenglld:pubmed
pubmed-article:6321535pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6321535pubmed:statusMEDLINElld:pubmed
pubmed-article:6321535pubmed:monthAprlld:pubmed
pubmed-article:6321535pubmed:issn0021-972Xlld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:ValuGGlld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:RivierJJlld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:OrthD NDNlld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:JacksonR VRVlld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:DeBoldC RCRlld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:DeCherneyG...lld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:SheldonW RWRlld:pubmed
pubmed-article:6321535pubmed:authorpubmed-author:AlexanderA...lld:pubmed
pubmed-article:6321535pubmed:issnTypePrintlld:pubmed
pubmed-article:6321535pubmed:volume58lld:pubmed
pubmed-article:6321535pubmed:ownerNLMlld:pubmed
pubmed-article:6321535pubmed:authorsCompleteYlld:pubmed
pubmed-article:6321535pubmed:pagination740-3lld:pubmed
pubmed-article:6321535pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:meshHeadingpubmed-meshheading:6321535-...lld:pubmed
pubmed-article:6321535pubmed:year1984lld:pubmed
pubmed-article:6321535pubmed:articleTitleSynthetic ovine corticotropin-releasing hormone: simultaneous release of proopiolipomelanocortin peptides in man.lld:pubmed
pubmed-article:6321535pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6321535pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:6321535pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed